Annual Report, page-14

dilu
Over the last 3-4 reporting cycles, they have generally delivered per guidance; in fact they indicated in May that they would deliver EPS of 15.5c for FY2019 and ~19c including the Bilbac transation so can't see why they would be too far off that (definitely should not be materially under, but can't see them being too far over).

The purchase in NZ, ACL and then Volt is not expected to contribute anything material this half (not sure why NZ & ACL would not & contribute something given NZ was ~Jan), but if you review their announcements when purchased, the sum of those 3 purchases will add EPS of ~5c. So you won't see much progress on this front tomorrow.

My big bugbear with this business is the lack of organic growth despite saying they improving collections, PDL quality etc etc. Lets see the message tmr & then likely will have to wait until Feb to see the execution & integration of the purchases